Hormonal Therapy is treatment that adds, blocks, or removes hormones. For certain conditions (such as diabetes or menopause), hormones are given to adjust low hormone levels. To slow or stop the growth of certain cancers (such as prostate and breast cancer), synthetic hormones or other drugs may be given to block the body’s natural hormones. Sometimes surgery is needed to remove the gland that makes a certain hormone. Also called endocrine therapy, hormone therapy, and hormone treatment.
Immunotherapy has been disappointing as a prostate cancer treatment, but a new Columbia study suggests that the powerful treatments have potential when the disease starts to spread.
Researchers assessed ethnic and racial differences in novel hormonal therapy (NHT) use among advanced prostate cancer (PCa) patients.
A new study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center found Black men diagnosed with more advanced stages of prostate cancer are significantly less likely to be prescribed novel hormone therapy than other racial and ethnic groups – including white or Latino men – despite the therapy being proven to effectively control the growth of prostate tumors and extend the lives of men with the disease.
Study finds no independent link between dietary fats and androgen levels in middle-aged men; however, replacing protein calories with saturated fatty acids may raise serological androgen levels, suggesting diet's potential impact on male hormonal health.
The authors of the revised 2023 Toolkit extracted key recommendations from professional guidelines and positions as well as consensus statements on menopause and related conditions that have emerged since 2014.
Can lifestyle interventions such as exercise and intermittent fasting help patients with advanced breast cancer better tolerate side effects from treatment?
People with intermediate risk, localized prostate cancer can be treated as effectively using fewer and higher doses of radiation therapy delivered over five treatment sessions as they can with lower doses delivered over several weeks, a new phase III randomized trial suggests.
Researchers at the University of Chicago Medicine Comprehensive Cancer Center established "proof-of-concept" for a new treatment approach that was able to effectively treat the most aggressive forms of prostate cancer. The treatment showed complete tumor control and long-lasting survival without side effects in a mouse model of advanced prostate cancer.
In elderly patients with suspected prostate cancer, PSMA PET/CT can diagnose advanced disease and aid in therapy selection without the need for a biopsy.
A three-year-long retrospective cohort study of a single Atlanta hospital's patient population found transgender and gender-diverse teenagers rarely chose to discontinue gender-affirming hormone therapy, according to a study being presented Sunday at ENDO 2023, the Endocrine Society's annual meeting in Chicago, Ill.
A recent BMC Women's Health study performed a survey to understand how bacterial vaginosis affects women’s quality of life and what treatment they underwent.
Endometriosis is a painful, complex condition affecting about 1 in 10 women of reproductive age, but it is poorly understood.
A new study finds that recent increases in Medicare spending on outpatient cancer care at the end of patients' lives were driven almost entirely by a type of treatment given to fewer than 1 in 5 patients.
For men with early-stage prostate cancer being managed by active surveillance, adding the hormonal agent apalutamide may lower the rate of positive biopsies during follow-up, suggests a preliminary clinical trial in The Journal of Urology, an Official Journal of the American Urological Association.
Investigators at Cedars-Sinai have created a unique and detailed molecular profile of endometriosis to help improve therapeutic options for the millions of women suffering from the disease.
Up to 15% of women of reproductive age in the United States suffer from endometriosis, a condition characterized by pelvic pain, menstrual cramps and infertility.
A UCLA Jonsson Comprehensive Cancer Center researcher and collaborators in a multicenter study will present updated results and plans for further research on a new approach to treating advanced ER-positive/HER2-negative breast cancer.
New research from Yale Cancer Center identified that two simple biomarkers, immune cells and estrogen receptor levels, could differentiate which young women with ER+ breast cancer need chemotherapy to improve their survival, and which only need a monthly injection to suppress ovarian function.
For high-risk patients with prostate cancer, treatment with novel hormonal agents (NHAs) followed by surgery can reduce the risk of recurrent and progressive cancer, compared to initial treatment with surgery, suggests a study in The Journal of Urology®, an Official Journal of the American Urological Association (AUA).
Researchers explored the molecular and cellular mechanisms of SARS-CoV-2 infection.